Roca.....just where do we find such a "Successful, seasoned CEO", who will take over a promising yet presently non-commercial biotech and what would you suspect we would have to pay them? In essence, we are diluting in the short term. What is more reasonablele is to Partner" with a mature BioPharma which has all the commercial capabilities such as research, marketing, public relations, legal, production. sales and distribution which our small biotech doesn't have. Anavex can maintain control of the pipeline while accelerating the development of our drugs.
News 
Market Data 
Discover 
